SARC019

May 5, 2021

Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients

TYPE OF SARCOMA: Metastatic GIST
DRUG: Imatinib

ACCRUAL STATUS: Terminated

OVERALL STUDY PRINCIPAL INVESTIGATOR:
Suzanne George, MD
Dana-Farber Cancer Institute

CLINICALTRIALS.GOV IDENTIFIER: NCT01031628

FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV

To learn more about this study or to contact the study research staff:

contact sarc

Back to top